Entera Bio ENTX
NASDAQ ENTX
$3.22 -0.02 (-0.62%)
At close: Nov 11, 2026 · 4:00 PM EST

Entera Bio (ENTX) Current Deferred Revenue (2018 - 2021)

Updated

Entera Bio (ENTX) reported Current Deferred Revenue of $15,000 for Q4 2021, down 90.5% from $158,000 a year earlier.

Analysis

Entera Bio (ENTX) Current Deferred Revenue (2018 - 2021) Analysis & Trends

  • By year, Current Deferred Revenue came in at $158,000 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Entera Bio 563.51 Mn 269.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 15,000.00
Jun 30, 2021 8,000.00
Mar 31, 2021 15,000.00
Dec 31, 2020 158,000.00
Sep 30, 2020 123,000.00
Jun 30, 2020 173,000.00
Mar 31, 2020 225,000.00
Dec 31, 2019 267,000.00
Sep 30, 2019 91,000.00
Jun 30, 2019 151,000.00
Mar 31, 2019 225,000.00
Dec 31, 2018 225,000.00
API Access

Entera Bio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ENTX&period=max&api_key=YOUR_API_KEY